Iperion emerges as a $1.6m cash shell after issuer transition from SNC

The announcement was lodged under the SNC ticker and carries an issuer-transition flag, so the prior comparable column reflects a substantially larger predecessor entity (FY22 total assets NZ$2b, revenue NZ$11.3m, NPAT loss NZ$164.7m) rather than the same operating business now trading as Iperion. The current entity reports NZ$0.026m of interest income, a PBT loss of NZ$0.3m, NZ$0.4m of cash and NZ$1.7m of total assets, with equity of NZ$1.6m against just NZ$0.1m of liabilities.

Headline movements are therefore mechanical: revenue down 99.8% and PBT/NPAT both improving 99.8% as the prior entity's loss base disappears. Operating cash outflow narrowed from NZ$119.1m to NZ$0.4m on the same basis.

• Annolyse's historical baseline classifies PBT and NPAT growth as above the recent range, but those classifications are arithmetic artefacts of the transition; with no continuing operating revenue and only interest income, there is no underlying earnings stream to project forward. Treating the +99.8% PBT print as durable would misread the filing.
• Capital runway is the binding question. Cash of NZ$0.4m sits against an FY23 operating cash burn of NZ$0.4m, implying roughly a year of runway at the current cost base before further funding is required. Equity of NZ$1.6m provides limited cushion, and ROE of -17.2% (weakened from -8.6% on the predecessor base) is now being calculated against a much smaller denominator, so any incremental loss compounds quickly.
• Strategy is search-driven and unconcluded. The interim-context overlay flags an acquisition focus, and the HY23 release stated the company "continues to look for appropriate acquisition targets with the support of the majority" shareholder. No target, structure or funding plan has been disclosed in this announcement, so the investment case rests entirely on a future transaction rather than on FY23 economics.

There is no dividend, and management has confirmed none is proposed. The second-half shape calculation (H1 representing 38.5% of full-year revenue and 47.1% of the NPAT loss) is technically computed but economically meaningless at these absolute amounts.

The release does not support any view on revenue trajectory, margin or returns; it supports only the observation that Iperion entered FY24 as a small-cap search vehicle with limited cash, no operating activity and an unannounced acquisition pipeline.

The NZ$0.3m loss is essentially the running cost of maintaining a listed shell, offset by NZ$26k of interest income on residual cash. The reported OCF/EBITDA ratio of 145.7% is a structural reflection of a non-cash item inside a tiny loss, not evidence of cash-generative operations.

The more important quality observation is balance-sheet, not income-statement. Total assets contracted 99.9% versus the predecessor, equity contracted 99.9%, and cash fell from NZ$21.7m to NZ$0.4m. Whatever value was attached to the prior NZ$1.9bn equity base did not migrate into the new Iperion shell, so the FY23 starting position is what matters for any future deal — and that position is thin. Any acquisition will almost certainly require an equity raise or vendor scrip, which means current holders should expect dilution as the primary mechanism by which a real business is introduced.

This briefing cannot assess the probability, valuation or terms of any future acquisition that would convert Iperion from a cash shell into an operating business.